|

Xospata Clinical Trials

1 actively recruiting trial

Also known as: Gilteritinib

Pipeline

Phase 2: 1

Top Sponsors

  • French Innovative Leukemia Organisation1

Indications

  • FLT3-ITD1
  • FLT3-TKD Mutation1
  • Relapsed Adult AML1
  • AML, Adult1
  • Refractory AML1

Other1 trial

Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.